Food and Drug Administration (FDA) added Ozempic and Wegovy to its Drug Shortages List
Many of these employers have considered scaling back coverage of GLP-1 agonists for weight loss, or in some cases, employers are adding or strengthening coverage requirements
Insufficient caloric deficit, too much caloric intake within the eating window, medication dose not yet optimized, metabolic adaptation, or an underlying condition affecting metabolism
Appropriate for patients managing adrenal fatigue, high-demand schedules, or post-illness recovery
In this study, Smits et al
For example, a smaller amuse-bouche, a 5 oz